Clinical Trial Update: Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Asian Patients With Essential Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial compared LCZ696 (sacubitril/valsartan) with olmesartan in Asian patients with essential hypertension to assess efficacy and safety, with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• LCZ696 (sacubitril/valsartan)
• Olmesartan (olmesartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2015-09-04